Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science

Veterinary Pathology

Volumn 49, Issue 1, 2012, Pages 16-23

  Urano, K ^a   Tamaoki, N ^a   Nomura, T ^a  

^a CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

carcinogenicity; rasH2 mice; short term study

Indexed keywords

ANIMAL; ANIMAL MODEL; ARTICLE; CARCINOGEN TESTING; CHEMICALLY INDUCED DISORDER; DRUG CONTROL; EXPERIMENTAL NEOPLASM; FEMALE; FOUNDER EFFECT; HUMAN; MALE; METHODOLOGY; MOUSE; PHENOTYPE; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENICITY TESTS; DRUG AND NARCOTIC CONTROL; FEMALE; FOUNDER EFFECT; HUMANS; MALE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NEOPLASMS, EXPERIMENTAL; PHENOTYPE;

ANIMALIA; MUS;

EID: 84855393011     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985811430318     Document Type: Article

References (17)

1. Alden CL,Lynn A,Bourdeau A, et al.A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk.Vet Pathol. 2011;48 (3): 772-784.
2. Cohen JB,Levinson AD.A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene.Nature. 1988;334:119-124.
3. Green ELGenetics and Probability in Animal Breeding Experiments. New York, NY: Oxford University Press; 1981:.
4. Jacobson-Kram D.Cancer risk assessment approaches at the FDA/CDER: is the era of the 2-year bioassay drawing to a close?.Toxicol Pathol. 2010;38 (1): 169-170.
5. Jin M,Takahashi M,Moto M, et al.Carcinogenic susceptibility of rasH2 mice to troglitazone.Arch Toxicol. 2007;81 (12): 883-894.
6. Long GG,Morton D,Peters T, et al.Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.Toxicol Pathol. 2010;38 (1): 43-50.
7. MacDonald J,French JE,Gerson RJ, et al.The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward.Toxicol Sci. 2004;77 (2): 188-194.
8. Machida K,Urano K,Yoshimura M, et al.Carcinogenic comparative study on rasH2 mice produced by two breeding facilities.J Toxicol Sci. 2008;33 (4): 493-501.
9. Mitsumori K,Wakana S,Yamamoto S, et al.Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors.Mol Carcinog. 1997;20 (3): 298-307.
10. Mitsumori K,Koizumi H,Nomura T, et al.Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.Toxicol Pathol. 1998;26 (4): 520-531.
11. Nomura T,Esaki K,Tomita TICLAS Manual for Genetic Monitoring of Inbred Mice. Tokyo, Japan: University of Tokyo Press; 1980:23-110.
12. Saitoh A,Kimura M,Takahashi R, et al.Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes.Oncogene. 1990;5 (8): 1195-1200.
13. Storer RD,Sistare FD,Reddy MV, et al.An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.Toxicol Pathol. 2010;38 (1): 51-61.
14. Suemizu H,Kito-Maruyama C,Sotomaru Y, et al.PCR method for genotyping and zygosity-testing of rasH2 transgenic mice.Exp Anim. 2004;53 (5): 463-466.
15. Usui T,Mutai M,Hisada S, et al.CB6F1-rasH2 mouse: overview of available data.Toxicol Pathol. 2001;29 (suppl): 90-108.
16. Yamamoto S,Mitsumori K,Kodama Y, et al.Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.Carcinogenesis. 1996;17 (11): 2455-2461.
17. Yamamoto S,Urano K,Koizumi H, et al.Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.Environ Health Perspect. 1998;106 (suppl 1): 57-69.